IP Library › Granted Patent US 12,655,211
Granted Patent B2
US 12,655,211 · App. 18/145,254 · Granted Jun 16, 2026

Antibodies targeting G-protein coupled receptor and methods of use

Inventors: Renier J. Brentjens (New York, NY); Eric L. Smith (New York, NY); Cheng Liu (Emeryville, CA); Hong Liu (Emeryville, CA)
Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER; EUREKA THERAPEUTICS, INC.
C07K16/28A61K47/6849A61P35/00C07K16/2809G01N33/6872C07K2317/21C07K2317/24C07K2317/31C07K2317/34C07K2317/622C07K2317/92C07K2319/21G01N2333/705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,655,211
App. No.
18/145,254
Granted
Jun 16, 2026
Kind
B2
Abstract

The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.

Claims (90)

1 . An anti-human G-protein coupled receptor family C group 5 member D (GPRC5D) single chain variable fragment (scFv) comprising a light chain variable region, a heavy chain variable region, and a peptide linker, wherein:

(i) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 124; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 125; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 126; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 127; a CDR2 comprising amino acids having the sequence of DNN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 129;

(ii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 130; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 131; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 132; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 133; a CDR2 comprising amino acids having the sequence of DDN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 135;

(iii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 136; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 137; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 138; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 139; a CDR2 comprising amino acids having the sequence of AAS; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 141;

(iv) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 142; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 143; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 144; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 145; a CDR2 comprising amino acids having the sequence of DVS; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 147;

(v) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 148; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 149; a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 150; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 151; a CDR2 comprising amino acids having the sequence of RNH; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 153;

(vi) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 154; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 155; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 156; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 157; a CDR2 comprising amino acids having the sequence of RNN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 159;

(vii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 160; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 161; a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 162; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 163; a light chain variable region CDR2 comprising amino acids having the sequence of EVS; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 165;

(viii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 166; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 167; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 168; and the light chain variable region comprises CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 169; a CDR2 comprising amino acids having the sequence of RNN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 171;

(ix) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 172; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 173; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 174; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 175; a CDR2 comprising amino acids having the sequence of RNN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 177;

(x) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 178; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 179; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 180; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 181; a CDR2 comprising amino acids having the sequence of DVS; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 183;

(xi) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 184; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 185; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 186; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 187; a CDR2 comprising amino acids having the sequence of RNN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 189;

(xii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 190; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 191; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 192; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 193; a CDR2 comprising amino acids having the sequence of EVT; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 195;

(xiii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 196; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 197; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 198; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 199; a CDR2 comprising amino acids having the sequence of GNS; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 201;

(xiv) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 202; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 203; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 204; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 205; a CDR2 comprising amino acids having the sequence of DVS; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 207;

(xv) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 208; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 209; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 210; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 211; a CDR2 comprising amino acids having the sequence of DVF; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 213;

(xvi) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 214; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 215; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 216; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 217; a CDR2 comprising amino acids having the sequence of RSN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 219;

(xvii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 220; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 221; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 222; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 223; a CDR2 comprising amino acids having the sequence of GKN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 225;

(xviii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 226; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 227; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 228; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 229; a CDR2 comprising amino acids having the sequence of DND; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 231;

(xix) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 232; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 233; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 234; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 235; a CDR2 comprising amino acids having the sequence of EVS; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 237;

(xx) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 238; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 239; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 240; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 241; a CDR2 comprising amino acids having the sequence of EVN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 243;

(xxi) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 244; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 245; and a CDR3 comprising amino acids having the sequence set forth ACTIVE 513198183.1 6 in SEQ ID NO: 246; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 247; a CDR2 comprising amino acids having the sequence of EVN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 249;

(xxii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 250; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 251; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 252; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 253; a CDR2 comprising amino acids having the sequence of DNN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 255;

(xxiii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 256; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 257; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 258; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 259; a CDR2 comprising amino acids having the sequence of EVS; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 261;

(xxiv) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 262; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 263; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 264; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 265; a CDR2 comprising amino acids having the sequence of GVS; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 267;

(xxv) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 268; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 269; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 270; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 271; a CDR2 comprising amino acids having ACTIVE 513198183.1 7 the sequence of EVT; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 273;

(xxvi) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 280; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 281; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 282; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 283; a CDR2 comprising amino acids having the sequence of SNN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 285;

(xxvii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 292; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 293; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 294; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 295; a CDR2 comprising amino acids having the sequence of RNN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 297;

(xxviii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 303; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 304; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 305; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 306; a CDR2 comprising amino acids having the sequence of RNN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 308;

(xxix) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 316; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 317; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 318; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 319; a CDR2 comprising amino acids having the sequence of GNS; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 321;

(xxx) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 328; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 329; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 330; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 331; a CDR2 comprising amino acids having the sequence of DNN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 333;

(xxxi) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 340; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 341; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 342; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 343; a CDR2 comprising amino acids having the sequence of EVT; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 345; or

(xxxii) the heavy chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 352; a CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 353; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 354; and the light chain variable region comprises a CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 355; a CDR2 comprising amino acids having the sequence of RNN; and a CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 357.

2 . The anti-human GPRC5D scFv of claim 1 , wherein:

(a) the heavy chain variable region comprises the amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 274, 286, 298, 310, 322, 334, 346 and 358; and

(b) the light chain variable region comprises the amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, 94, 275, 287, 299, 311, 323, 335, 347 and 359.

3 . The anti-human GPRC5D scFv of claim 1 , wherein the heavy chain variable region and the light chain variable region are selected from the group consisting of:

(i) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:1, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:2;

(ii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:5, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:6;

(iii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:9, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:10;

(iv) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:13, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:14;

(v) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:17, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:18;

(vi) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:21, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:22;

(vii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:25, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:26;

(viii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:29, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 30;

(ix) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:33, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:34;

(x) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:37, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:38;

(xi) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:41, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:42;

(xii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:45, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:46;

(xiii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:49, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:50;

(xiv) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:53, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:54;

(xv) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:57, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:58;

(xvi) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:61, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:62;

(xvii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:65, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:66;

(xviii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:69, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:70;

(xix) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:73, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:74;

(xx) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:77, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:78;

(xxi) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:81, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 82;

(xxii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:85, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:86;

(xxiii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:89, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:90;

(xxiv) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:93, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:94;

(xxv) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:274, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:275;

(xxvi) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:286, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:287;

(xxvii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:298, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:299;

(xxviii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:310, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:311;

(xxix) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:322, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:323;

(xxx) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:334, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:335;

(xxxi) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:346, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:347; or

(xxxii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:358, and a light chain variable region comprising amino acids the sequence set forth in SEQ ID NO:359.

4 . The anti-human GPRC5D scFv of claim 1 , wherein the GPRC5D comprises the amino acid sequence set forth in SEQ ID NO:97.

5 . The anti-human GPRC5D scFv of claim 1 , wherein the scFv comprises the amino acid sequence selected from the group consisting of SEQ ID NOS: 100-123, 276, 288, 300, 312, 324, 336, 348 and 360.

6 . A composition comprising the anti-human GPRC5D scFv antibody of claim 1 , and a pharmaceutically acceptable carrier.

7 . An immunoconjugate comprising the anti-human GPRC5D scFv antibody of claim 1 , linked to a therapeutic agent.

8 . The immunoconjugate of claim 7 , wherein said therapeutic agent is a drug.

9 . A composition comprising the immunoconjugate of claim 7 and a pharmaceutically acceptable carrier.

10 . A bispecific molecule comprising the anti-human GPRC5D scFv of claim 1 , linked to a second functional moiety.

11 . The bispecific molecule of claim 10 , wherein the second functional moiety has a different binding specificity than said anti-human GPRC5D scFv.

12 . The bispecific molecule of claim 11 , wherein the second functional moiety has a binding specificity for an immune cell.

13 . The bispecific molecule of claim 11 , wherein the second functional moiety has a binding specificity for CD3.

14 . A composition comprising the bispecific molecule of claim 10 and a pharmaceutically acceptable carrier.

15 . A nucleic acid that encodes an anti-human GPRC5D scFv of claim 1 .

16 . An expression vector comprising the nucleic acid molecule of claim 15 .

17 . A host cell comprising the expression vector of claim 16 .

18 . A method for detecting GPRC5D in a whole cell or tissue, comprising:

contacting a cell or tissue with the anti-human GPRC5D scFv of claim 7 , wherein said anti-human GPRC5D scFv comprises a detectable label; and

determining the amount of the labeled anti-human GPRC5D scFv bound to said cell or tissue by measuring the amount of detectable label associated with said cell or tissue, wherein the amount of bound anti-human GPRC5D scFv indicates the amount of GPRC5D in said cell or tissue.

19 . The anti-human GPRC5D scFv of claim 1 , wherein the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:220, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:221, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:222; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:223, a CDR2 comprising the amino acid sequence of GKN, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:225.

20 . The anti-human GPRC5D scFv of claim 1 , comprising the amino acid sequence set forth in SEQ ID NO:116.

21 . The immunoconjugate of claim 7 , wherein said therapeutic agent is a cytotoxin.

22 . The immunoconjugate of claim 7 , wherein said therapeutic agent is a radioactive isotope.

Assignments (4)
MERGER Recorded Aug 18, 2026
From: EUREKA THERAPEUTICS, INC., A CALIFORNIA CORPORATION
To: EUREKA THERAPEUTICS, INC., A DELAWARE CORPORATION
Reel/Frame 075688/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2026
From: BRENTJENS, RENIER J.; SMITH, ERIC L.
To: MEMORIAL SLOAN-KETTERING CANCER CENTER
Reel/Frame 074577/0642 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2026
From: LIU, CHENG
To: EUREKA THERAPEUTICS, INC.
Reel/Frame 074578/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2026
From: LIU, HONG
To: EUREKA THERAPEUTICS, INC.
Reel/Frame 074543/0343 →
Continuity (5)
Continuation 16732022 · Dec 31, 2019
Division 15614290 · Jun 5, 2017
Continuation PCTUS2015064122 · Dec 4, 2015
Provisional Application 62088228 · Dec 5, 2014
Related Publication 20240076370A1 · Mar 7, 2024
References Cited (337)
US 4956778A · Naito · 1990 [cited by applicant]
US 5091513A · Huston et al. · 1992 [cited by applicant]
US 5132405A · Huston et al. · 1992 [cited by applicant]
US 5399346A · Anderson et al. · 1995 [cited by applicant]
US 6588543B1 · Tchilinguirian et al. · 2003 [cited by applicant]
US 7083785B2 · Browning et al. · 2006 [cited by applicant]
US 7446190B2 · Sadelain et al. · 2008 [cited by applicant]
US 7483544B2 · Wright et al. · 2009 [cited by applicant]
US 7605236B2 · Ruben et al. · 2009 [cited by applicant]
US 7807163B2 · Law et al. · 2010 [cited by applicant]
US 8389282B2 · Sadelain et al. · 2013 [cited by applicant]
US 9994633B2 · Deshpande et al. · 2018 [cited by applicant]
US 10098951B2 · Lu et al. · 2018 [cited by applicant]
US 10464988B2 · Lu et al. · 2019 [cited by applicant]
US 10590196B2 · Brentjens · 2020 [cited by examiner]
US 10633426B2 · Brentjens · 2020 [cited by examiner]
US 10906956B2 · Brentjens · 2021 [cited by examiner]
US 11566071B2 · Brentjens · 2023 [cited by examiner]
US 11820806B2 · Brentjens · 2023 [cited by examiner]
US 11866478B2 · Brentjens · 2024 [cited by examiner]
US 12077592B2 · Attar · 2024 [cited by examiner]
US 20030207288A1 · Lewin et al. · 2003 [cited by applicant]
US 20040110139A1 · Monia et al. · 2004 [cited by applicant]
US 20050019320A1 · Sugaru et al. · 2005 [cited by applicant]
US 20050196754A1 · Drmanac et al. · 2005 [cited by applicant]
US 20080057063A1 · Rinkenberger et al. · 2008 [cited by applicant]
US 20110166330A1 · Kobilka et al. · 2011 [cited by applicant]
US 20130130379A1 · Adams et al. · 2013 [cited by applicant]
US 20140322183A1 · Milone et al. · 2014 [cited by applicant]
US 20150306141A1 · Jensen et al. · 2015 [cited by applicant]
US 20160158359A1 · Gilbert · 2016 [cited by applicant]
US 20160289293A1 · Pule et al. · 2016 [cited by applicant]
US 20160303230A1 · Ahmed et al. · 2016 [cited by applicant]
US 20160333114A1 · Williams · 2016 [cited by applicant]
US 20170335281A1 · Loew et al. · 2017 [cited by applicant]
US 20180110002A1 · Kim et al. · 2018 [cited by applicant]
US 20180118803A1 · Brentjens et al. · 2018 [cited by applicant]
US 20180118822A1 · Brentjens et al. · 2018 [cited by applicant]
US 20180258149A1 · Motz et al. · 2018 [cited by applicant]
US 20190107537A1 · Chaudhary · 2019 [cited by applicant]
US 20190112380A1 · Chaudhary · 2019 [cited by applicant]
US 20190248865A1 · Lu et al. · 2019 [cited by applicant]
US 20190367612A1 · Chaen et al. · 2019 [cited by applicant]
US 20200123249A1 · Brentjens et al. · 2020 [cited by applicant]
US 20200270326A1 · Brentjens et al. · 2020 [cited by applicant]
US 20200270327A1 · Brentjens et al. · 2020 [cited by applicant]
US 20200270328A1 · Brentjens et al. · 2020 [cited by applicant]
US 20210393689A1 · Sather et al. · 2021 [cited by applicant]
US 20240294599A1 · Brentjens · 2024 [cited by examiner]
CN 103483452 · 2014 [cited by applicant]
CN 103483453 · 2014 [cited by applicant]
CN 105647873 · 2016 [cited by applicant]
CN 108239144 · 2018 [cited by applicant]
EP 1468694A1 · 2004 [cited by applicant]
EP 4582449A1 · 2025 [cited by examiner]
RU 2526517C2 · 2014 [cited by applicant]
WO WO03055507A1 · 2003 [cited by applicant]
WO WO2004072117A2 · 2004 [cited by applicant]
WO WO2005019258A2 · 2005 [cited by applicant]
WO WO2005097185 · 2005 [cited by applicant]
WO WO2009039192A2 · 2009 [cited by applicant]
WO WO2009101611A1 · 2009 [cited by applicant]
WO WO2011083088A2 · 2011 [cited by applicant]
WO WO2012009790A1 · 2012 [cited by applicant]
WO WO2012079000A1 · 2012 [cited by applicant]
WO WO2013033626A2 · 2013 [cited by applicant]
WO WO2013185552 · 2013 [cited by applicant]
WO WO2014031687 · 2014 [cited by applicant]
WO WO2014087010A1 · 2014 [cited by applicant]
WO WO2014114800A1 · 2014 [cited by applicant]
WO WO2014127261A1 · 2014 [cited by applicant]
WO WO2014191128A1 · 2014 [cited by applicant]
WO WO2015095895 · 2015 [cited by applicant]
WO WO2015105522 · 2015 [cited by applicant]
WO WO2015121454 · 2015 [cited by applicant]
WO WO2015142675A2 · 2015 [cited by applicant]
WO WO2016001810A1 · 2016 [cited by applicant]
WO WO2016014530A1 · 2016 [cited by applicant]
WO WO2016090312A1 · 2016 [cited by applicant]
WO WO2016090327 · 2016 [cited by applicant]
WO WO2016090329 · 2016 [cited by applicant]
WO WO2016126608 · 2016 [cited by applicant]
WO WO2016210293 · 2016 [cited by applicant]
WO WO2017049166 · 2017 [cited by applicant]
WO WO2017062628 · 2017 [cited by applicant]
WO WO2017070608 · 2017 [cited by applicant]
WO WO2017149515 · 2017 [cited by applicant]
WO WO2017172981 · 2017 [cited by applicant]
WO WO2017181119 · 2017 [cited by applicant]
WO WO2017222593 · 2017 [cited by applicant]
WO WO2018017786 · 2018 [cited by applicant]
WO WO2019154890 · 2019 [cited by applicant]
WO WO2020092854 · 2020 [cited by applicant]
Almagro & Franssen, Frontiers in Bioscience, 13:1619-33 (2008). [cited by examiner]
Edwards et al., J Mol Biol 334:103-118 (2003). [cited by examiner]
Marchalonis et al., Dev & Comp Immunol. 30:223-247 (2006). [cited by examiner]
Lippow et al., Nature Biotechnology, 25(10):1171-1176 (2007). [cited by examiner]
Sulea et al., Scientific Reports, 8(260):1-11 (2018). [cited by examiner]
Hasegawa et al.,MABS, vol. 9, No. 5, pp. 854-873 (2017). [cited by examiner]
Altshuler et al., Biochemistry (Moscow), 75(13):1584-1605 (2010). [cited by examiner]
Vajda et al., Current Opinion in Structural Biology, 67 pp. 226-231 (2021). [cited by examiner]
Marks et al., J. Biol. Chem. 295(29) 9823-9837 (2020). [cited by examiner]
Akbar et al., Cell Reports 34, 108856, Mar. 16, 2021. [cited by examiner]
Lo et al., BMC Genomics vol. 22, Article No. 116 (2021). [cited by examiner]
Ali et al., “T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma,” Blood (2016) 128(13):1688-1700. [cited by applicant]
Almagro et al., “Humanization of antibodies,” Front Biosci (Jan. 2008) 13:1619-33. [cited by applicant]
Barderas et al., “Affinity maturation of antibodies assisted by in silico modeling,” Proc Natl Acad Sciences, Natl Aca Sci USA (2008) 105(26):9029-34. [cited by applicant]
Berahovich et al., “CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth,” Cancers (Basel) (2018) 10(9):323, 16 pages. [cited by applicant]
Brentjens et al., 2016 (Geneseq Accession No. BDB11168, computer printout, p. 1) (Brentjens SEQ ID No. 21). [cited by applicant]
Brentjens et al., 2016 (Geneseq Accession No. BDB11169, computer printout, p. 1) (Brentjens SEQ ID No. 22). [cited by applicant]
Brudno J et al., “T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma,” J Clin. Oncol. (2018) 36(22):2267-80. [cited by applicant]
Carpenter et al., “B-cell Maturation Antigen is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma,” Clin Cancer Res. 19(8):2048-2060 (2013). [cited by applicant]
Chen et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations,” EMBO J (Jun. 1995) 14(12):2784-94. [cited by applicant]
Cho et al., “BCMA CAR T-cell therapy arrives for multiple myeloma: a reality,” Ann Transl Med (2018) 6(Suppl 2):S93, 5 pages. [cited by applicant]
Curran et al., “Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions,” J Gene Med (2012) 14(6):405-415. [cited by applicant]
Ebert et al., “Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology,” Biochem Soc Trans (Apr. 2018) 46(2):391-401. [cited by applicant]
Hudecek et al., “Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells,” Clin. Cancer Res. (2013) 19:3153-3164. [cited by applicant]
Hudecek et al., “The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity,” Cancer Immunol Res (Feb. 2015, e-pub. Sep. 11, 2014) 3(2):125-135. [cited by applicant]
Koenig et al., “Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding,” Proc Natl Acad Sci USA (Jan. 2017) 114(4):E486-E495. [cited by applicant]
Kussie et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity,” J Immunol. (Jan. 1994) 152(1):146-52. [cited by applicant]
Maynard et al., “Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity,” Nature Biotech (2002) 20(6):597-601. [cited by applicant]
Smith et al., “CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for Immunotherapy of Myelom,” ASH Annual Meeting 2018. Presentation. Presented on Dec. 3, 2018, 27… [cited by applicant]
Smith et al., “Development and Evaluation of a Human scFv Derived BCMA Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM,” Presented at 2017 ASH annual meeting. Presentation… [cited by applicant]
Smith et al., “Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived BCMA Targeted Car T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM,” Blood (2017) 130:… [cited by applicant]
Smith et al., “Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted Car T Cell Vector,” Mol Ther. (2018) 26:1447-1456. [cited by applicant]
Smith et al., “Car T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma,” ASH 2018. Abstract 589. Presented on Dec. 3, 2018. [cited by applicant]
Tai et al., “Antibody-Based Therapies in Multiple Myeloma,” Bone Marrow Research (2011) Article ID: 924058, 14 pages. [cited by applicant]
Tai et al., “Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma,” Blood (May 15, 2014, e-pub. Feb. 25, 2014) 123(20):3128-38. [cited by applicant]
Tai et al., “Targeting B-cell maturation antigen in multiple myeloma,” Immunotherapy (2015) 7(11):1187-1199. [cited by applicant]
Wahl et al., “Molecular Hybridization of Immobilized Nucleic Acids: Theoretical Concepts and Practical Considerations,” Methods Enzymol. 152:399-407 (1987). [cited by applicant]
Winkler et al., “Changing the antigen binding specificity by single point mutations of an anti-pp24 (HIV-1) antibody,” J Immunol (2000) 165(8):4505-14. [cited by applicant]
Pearson, “An Introduction to Sequence Similarity (“Homology”) Searching,” Current Protocols in Bioinformatics, 42(1):3.1.1-3.1.8 (2013). [cited by applicant]
Anonymous, “GPRC5D Antibody (N-Terminus, APC) IHC-plus(TM) ILSA105978I LSBio—Bio-Connect,” Jan. 1, 2014 (Jan. 1, 2014), pp. 1-2, XP093046783, Retrieved from the Internet: URL:https://shop.bio-connect.nl/antibodies/gprc5… [cited by applicant]
U.S. Appl. No. 15/613,800 (US 2018/0118803), filed Jun. 5, 2017 (May 3, 2018). [cited by applicant]
U.S. Appl. No. 15/614,290 (U.S. Pat. No. 10,590,196), filed Jun. 5, 2017 (Mar. 17, 2020). [cited by applicant]
U.S. Appl. No. 16/731,973 (Abandoned), filed Dec. 31, 2019. [cited by applicant]
U.S. Appl. No. 16/732,022 (U.S. Pat. No. 11,566,071), filed Dec. 31, 2019 (Jan. 31, 2023). [cited by applicant]
U.S. Appl. No. 16/732,022, Dec. 22, 2022 Issue Fee Payment. [cited by applicant]
U.S. Appl. No. 16/732,022, Sep. 30, 2022 Notice of Allowance. [cited by applicant]
U.S. Appl. No. 16/732,022, Jul. 21, 2022 Response to Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 16/732,022, Apr. 25, 2022 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 15/613,800, Jan. 17, 2020 Amendment after Notice of Allowance. [cited by applicant]
U.S. Appl. No. 15/613,800, Jan. 30, 2020 Response to Amendment after Notice of Allowance. [cited by applicant]
U.S. Appl. No. 15/613,800, Feb. 5, 2020 Notice of Allowance. [cited by applicant]
U.S. Appl. No. 15/613,800, Feb. 21, 2020 Issue Fee Payment. [cited by applicant]
U.S. Appl. No. 15/613,800, Feb. 27, 2020 Notice of Allowance. [cited by applicant]
U.S. Appl. No. 15/613,800, Nov. 21, 2019 Notice of Allowance. [cited by applicant]
U.S. Appl. No. 15/613,800, Nov. 1, 2019 Response to Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 15/613,800, Aug. 2, 2019 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 15/613,800, May 1, 2019 Response to Restriction Requirement. [cited by applicant]
U.S. Appl. No. 15/613,800, Feb. 5, 2019 Restriction Requirement. [cited by applicant]
U.S. Appl. No. 15/614,290, Dec. 5, 2019 Amendment after Notice of Allowance. [cited by applicant]
U.S. Appl. No. 15/614,290, Dec. 9, 2019 Amendment after Notice of Allowance. [cited by applicant]
U.S. Appl. No. 15/614,290, Dec. 31, 2019 Issue Fee Payment. [cited by applicant]
U.S. Appl. No. 15/614,290, Oct. 2, 2019 Notice of Allowance. [cited by applicant]
U.S. Appl. No. 15/614,290, Aug. 22, 2019 Response to Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 15/614,290, May. 22, 2019 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 15/614,290, Mar. 19, 2019 Response to Restriction Requirement. [cited by applicant]
U.S. Appl. No. 15/614,290, Feb. 19, 2019 Applicant Initiated Interview Summary. [cited by applicant]
U.S. Appl. No. 15/614,290, Sep. 20, 2018 Restriction Requirement. [cited by applicant]
U.S. Appl. No. 16/731,973, Aug. 24, 2020 Notice of Abandonment. [cited by applicant]
U.S. Appl. No. 16/731,973, Aug. 10, 2020 Applicant Initiated Interview Summary. [cited by applicant]
U.S. Appl. No. 16/731,973, Feb. 14, 2020 Non-Final Office Action. [cited by applicant]
“Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-316 (Academic Pres… [cited by applicant]
Abbas et al., Cellular and Molecular Immunology, p. 54 (1991). [cited by applicant]
Abdiche et al., “Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors,” Protein Science 17:1326-1335 (2008). [cited by applicant]
Allen, “Ligand-Targeted Therapeutics in Anticancer Therapy,” Nat. Rev. Cancer 2:750-763 (2002). [cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res. 25(17):3389-3402 (1997). [cited by applicant]
Altschul, et al., “Basic Local Alignment Search Tool,” J. Mol. Biol. 215:403-410 (1990). [cited by applicant]
Amon et al., “Monoclonal Antibodies for Immunotargeting Of Drugs In Cancer Therapy,” in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-256 (1985). [cited by applicant]
Anderson, “Prospects for Human Gene Therapy,” Science 226(4673):401-409 (1984). [cited by applicant]
Arnon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”, in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-256 (Alan R. Liss, Inc. 1985). [cited by applicant]
Atamaniuk et al., “Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma,” European Journal of Clinical Investigation, 42(9):953-960 (2012… [cited by applicant]
Azinovic et al., “Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies,” Cancer Immunol Immunother 55:1451-1458 (2006). [cited by applicant]
Baeuerle et al., “Bispecific T-cell Engaging Antibodies for Cancer Therapy,” Cancer Res., 69(12):4941-4944 (2009). [cited by applicant]
Bam et al., “GPRC5D Is a Cell Surface Plasma Cell Marker Whose Expression Is High In Myeloma Cells and Reduced Following Coculture With Osteoclasts,” Blood 122:3099 (2013). [cited by applicant]
Bataille et al., “The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy,” Haematologica 91:1234-1240 (2006). [cited by applicant]
Beckman et al., “Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors,” Can. 109:170-179 (2007). [cited by applicant]
Benton et al., “Screening Xgt Recombinant Clones by Hybridization to Single Plaques in situ,” Science 196(4286):180-182 (1977). [cited by applicant]
Bertilaccio et al., “Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo,” Blood 122:4171 (2013). [cited by applicant]
Bird et al., “Single-Chain Antigen-Binding Proteins,” Science 242(4877):423-426 (1988). [cited by applicant]
Blömer et al., “Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector,” Journal of Virology 71(9):6641-6649 (1997). [cited by applicant]
Boyd et al., “The Clinical Impact and Molecular Biology of del(17p) in Multiple Myeloma Treated with Conventional or Thalidomide-Based Therapy,” Genes, Chromosomes & Cancer 50:765-774 (2011). [cited by applicant]
Bregni et al., “Human Peripheral Blood Hematopoietic Progenitors Are Optimal Targets of Retroviral-Mediated Gene Transfer,” Blood 80(6):1418-1422 (1992). [cited by applicant]
Brennan et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229:81-83 (1985). [cited by applicant]
Brentjens et al., “CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia,” Science Translational Medicine 5:177ra38 (2013). [cited by applicant]
Brentjens et al., “Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15,” Nature Medicine 9(3):279-286 (2003). [cited by applicant]
Brentjens et al., “Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts,” Clin Cancer Res 13(18):5426-5435 (2007). [cited by applicant]
Brentjens et al., “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias,” Blood 118(18):4817-4828 (2011). [cited by applicant]
Brigham et al., “Rapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle,” Am. J. Med. Sci. 298(4):278-281 (1989). [cited by applicant]
Brocks et al., “A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells,” Immunotechnology 3:173-184 (1997). [cited by applicant]
Brown et al., “Tolerance to Single, but not Multiple, Amino Acid Replacements in Antibody V-H CDR2: A Means of Minimizing B Cell Wastage from Somatic Hypermutation?” The Journal of Immunology, The American Association o… [cited by applicant]
Caron et al., “Engineered Humanized Dimeric Forms of IgG are More Effective Antibodies,” J Exp. Med 176:1191-1195 (1992). [cited by applicant]
Cayouette et al., “Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor Can Prevent Photoreceptor Degeneration in the Retinal Degeneration (rd) Mouse,” Human Gene Therapy 8:423-430 (1997). [cited by applicant]
Cespedes et al., “Mouse models in oncogenesis and cancer therapy,” Clin. Transl. Oncol. 8(5):318-329 (2006). [cited by applicant]
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” J. Mol. Biol. 293:865-881(1999). [cited by applicant]
Clinical Immunology and Allergology: in 3 volumes / edited by L. Yeger; translated from German by S.S. Kirzon, A.P. Portnova, Editor Academician R. V.Petrov—[2nd edition, reworked and updated].—Moscow: Meditsina, 1990. … [cited by applicant]
Cohen et al., “GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells,” Hematology 18(6):348-351 (2013). [cited by applicant]
Cornetta et al., “Gene Transfer into Primates and Prospects for Gene Therapy in Humans,” Progress in Nucleic Acid Research and Molecular Biology 36:311-322 (1987). [cited by applicant]
Cuesta et al., “Multivalent antibodies: when design surpasses evolution,” Trends in Biotechnology 28(7):355-362 (2010). [cited by applicant]
Culture of Animal Cells: A Manual of Basic Technique And Specialized Applications, Sixth Edition, Freshney, 2010 (Table of Contents). [cited by applicant]
Danos et al., “Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges,” PNAS USA 85:6460-6464 (1988). [cited by applicant]
Davila et al., “Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia,” Science Translational Medicine 6:224ra25 (2014). [cited by applicant]
Dennis et al., “Cancer: Off by a Whisker,” Nature 442:739-741 (2006). [cited by applicant]
Dudley et al., “Adoptive Cell Therapy for Patients with Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens,” J Clin Oncol 26:5233-5239 (2008). [cited by applicant]
Dupont et al., “Artificial Antigen-Presenting Cells Transduced with Telomerase Efficiently Expand Epitope-Specific, Human Leukocyte Antigen-Restricted Cytotoxic T Cells,” Cancer Res 65:5417-5427 (2005). [cited by applicant]
Edwards et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS,” J. Mol. Biol. 334:103-118 (2003). [cited by applicant]
Eglitis et al., “Retroviral Vectors for Introduction of Genes into Mammalian Cells,” BioTechniques 6(7):608-614 (1988). [cited by applicant]
Extended European Search Report dated Jul. 10, 2018 in Application No. EP 15865633. [cited by applicant]
Felgner et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,” PNAS USA 84:7413-7417 (1987). [cited by applicant]
Fife et al., “Inhibition of T cell activiation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist,” J Clin Invest 116(8):2252-2261 (2006). [cited by applicant]
Flatman et al., “Process analytics for purification of monoclonal antibodies,” J. Chromatogr. B 848:79-87 (2007). [cited by applicant]
Friedmann, “Progress toward Human Gene Therapy,” Science 244(4910):1275-1281 (1989). [cited by applicant]
Frigyesi et al., “Robust isolation of malignant plasma cells in multiple myeloma,” Blood 123(9):1336-1340 (2014). [cited by applicant]
Fujimori et al., “A Modeling Analysis of Monoclonal Antibody Percolation through Tumors: a Binding-Site Barrier,” J. Nucl. Med. 31:1191-I 198 (1990). [cited by applicant]
Gade et al., “Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes,” Cancer Res 65(19):9080-9088 (2005). [cited by applicant]
Gahrton et al., “Allogeneic Bone Marrow Transplantation in Multiple Myeloma,” N Engl J Med 325:1267-1273 (1991). [cited by applicant]
Gerd R, et al. Serological Analysis of Human Anti-Human Antibody Responses in Colon Cancer Patients Treated with Repeated Doses of Humanized Monoclonal Antibody A33. Cancer Res 2001; 61, 6851-6859. [cited by applicant]
Gershoni et al., “Epitope mapping—The first step in developing epitope-based vaccines,” Biod, Adis International Ltd., NZ, 21(3):145-156 (2007). [cited by applicant]
Giomarelli et al., “Inhibition of thrombin-induced platelet aggregation using human single-chain Fv antibodies specific for TREM-like transcript-I,” Thromb Haemost 97:955-963 (2007). [cited by applicant]
Glennie et al., “Preparation and performance of bispecific F(ab′ gamma)2 antibody containing thioether-linked Fab′ gamma fragments,” J. Immunol. 139:2367-2375 (1987). [cited by applicant]
Gong et al., “Cancer Patient T Cells Genetically Targeted to Prostate-Specific Membrane Antigen Specifically Lyse Prostate Cancer Cells and Release Cytokines in Response to Prostate-Specific Membrane Antigen,” Neoplasia… [cited by applicant]
Grunstein et al., “Colony hybridization: A method for the isolation of cloned DNAs that contain a specific gene,” PNAS USA 72(10):3961-3965 (1975). [cited by applicant]
Harris et al., “Crystallographic Structure of an Intact IgG1 Monoclonal Antibody,” Journal of Molecular Biology 275:861-872 (1998). [cited by applicant]
Hellstrom et al., “Antibodies for Drug Delivery,” in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-653 (1987). [cited by applicant]
Hirano et al., “Novel reciprocal regulation of cAMP signaling and apoptosis by orphan G-protein-coupled receptor GPRCSA gene expression,” Biochemical and Biophysical Research Communications 351:185-191(2006). [cited by applicant]
Ho et al., “Inhibition of Cocaine Binding to the Human Dopamine Transporter by a Single Chain Anti-Idiotypic Antibody: Its Cloning, Expression and Functional Properties,” BioChim Biophys Acta 1638(3):257-266 (2003). [cited by applicant]
Hollyman et al., “Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy,” J Immunother 32:169-180 (2009). [cited by applicant]
Huang et al., “Application in Antibody Research,” An Introduction to Bioinformatics, University of Electronic Science and Technology Press, pp. 160, (2014) (with full English translation). [cited by applicant]
Huang et al., “Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market,” Appl. Microbiol Biotechnol 87:401-410 (2010). [cited by applicant]
Hughes et al., “Retroviral Gene Transfer to Primitive Normal and Leukemic Hematopoietic Cells Using Clinically Applicable Procedures,” J. Clin. Invest. 89:1817-1824 (1992). [cited by applicant]
Hunder et al., “Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1,” N Engl J Med 358:2698-2703 (2008). [cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
International Search Report and Written Opinion dated Jul. 14, 2017 in International Patent Application No. PCT/US2017/032539, 12 pages. [cited by applicant]
International Search Report dated Apr. 8, 2016 in International Application No. PCT/US15/64102. [cited by applicant]
International Search Report dated May 19, 2016 in International Application No. PCT/US15/64122. [cited by applicant]
Johnson, “Gene Therapy for Cystic Fibrosis,” Chest 107:77S-83S (1995). [cited by applicant]
Kabat et al., Sequences of Proteins of Immunological Interest, 4th U. S. Department of Health and Human Services, National Institutes of Health (1987). [cited by applicant]
Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242. [cited by applicant]
Karpovsky et al., “Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fcy Receptor Antibodies,” J. Exp. Med. 160:1686-1701 (1984). [cited by applicant]
Kershaw et al., “Gene-Engineered T cells as a Superior Adjuvant Therapy for Metastatic Cancer,” J Immunol 173:2143-2150 (2004). [cited by applicant]
Kido et al., “Use of a retroviral vector with an internal opsin promoter to direct gene expression to retinal photoreceptor cells,” Current Eye Research 15:833-844 (1996). [cited by applicant]
Klechevsky et al., “Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts,” Cancer Res 68(15):6360-6367 (2008). [cited by applicant]
Kochenderfer et al., “Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells,” Blood (2010) 116(19):3875-3886. [cited by applicant]
Kodama et al., “Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma,” Mol. Cancer Ther. 18:1555-1564 (2019), Published Online first Jul. 3, 2019. [cited by applicant]
Koyko, R. Immunology: Textbook for Post-Graduate Education of Physicians / R. Koyko, D. Sunshine, E. Benjamin; translated from English, Editor N.B. Serebryanaya.—Moscow: Akademiya; Saint-Petersburg: Philology Department… [cited by applicant]
Koyko, R. Immunology: Textbook for Post-Graduate Education of Physicians / R. Koyko, D. Sunshine, E. Benjamin; translated from English, Editor N.B. Serebryanaya.—Moscow Akademiya; Saint-Petersburg: Philology Department … [cited by applicant]
Krause et al., “Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes,” J. Exp. Med. 188(4):619-626 (1998). [cited by applicant]
Le Gal La Salle et al., “An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain,” Science 259(5097):988-990 (1993). [cited by applicant]
Ledbetter et al., “Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from the Variable Regions of mAb G28-5,” Crit Rev Immunol. 17:427-435 (1997). [cited by applicant]
Lidij a P, et al. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 1997; 187(1 ): 9-18. [cited by applicant]
Lippincott-Schwartz et al., “Antibodies as Cell Biological Tools,” Chapter 16 in Current Protocols in Cell Biology Supplement 13, 16.0.1-16.0.2 (2002), 2 pages. [cited by applicant]
Lisa et al. Crystallographic structure of an intact lgG1 monoclonal antibody. Journal of Molecular Biology 1998; 275 (5): 861-872). [cited by applicant]
Liu et al., “Practical Internal Medicine Diagnosis and Treatment”, Multiple Myeloma, Hebei Science and Technology Press, p. 416 (2013). [cited by applicant]
Liu et al., “Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes,” Proc. Natl. Acad. Sci. USA 82:8648-8652 (1985). [cited by applicant]
Lloyd et al., “Modelling the human immune response: performance of a 10{circumflex over ( )}11 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Engineering, Design & Selecti… [cited by applicant]
Lyddane et al., “Cutting Edge: CD28 Controls Dominant Regulatory T Cell Activity During Active Immunization,” J. Immunol. 176:3306-3310 (2006). [cited by applicant]
Maher et al., “Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor,” Nat. Biotechnol. 20:70-75 (2002). [cited by applicant]
Mariuzza et al., “The Structural Basis Of Antigen-Antibody Recognition,” Annual Review of Biophysis and Biophysical Chemistry 16:139-159 (1987). [cited by applicant]
McCafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains,” Nature 348:552-554 (1990). [cited by applicant]
Myers et al., “Optimal alignments in linear space,” Cabios 4(1):11-17 (1988). [cited by applicant]
Miller et al., “Generation of Helper-Free Amphotropic Retroviruses That Transduce a Dominant-Acting, Methotrexate-Resistant Dihydrofolate Reductase Gene,” Mol. Cell. Biol. 5(3):431-437 (1985). [cited by applicant]
Miller et al., “Improved Retroviral Vectors for Gene Transfer and Expression,” Biotechniques 7(9):980-990 (1989). [cited by applicant]
Miller et al., “Redesign of Retrovirus Packaging Cell Lines to Avoid Recombination Leading to Helper Virus Production,” Mol. Cell. Biol. 6(8):2895-2902 (1986). [cited by applicant]
Miller, “Retrovirus Packaging Cells,” Human Gene Therapy 1:5-14 (1990). [cited by applicant]
Miyoshi et al., “Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector,” PNAS USA 94:10319-10323 (1997). [cited by applicant]
Moen, “Directions in Gene Therapy,” Blood Cells 17:407-416 (1991). [cited by applicant]
Moosmayer et al., “A single-chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity,” Therapeutic Immunol. 2:31-40 (1995). [cited by applicant]
Morgan et al., “Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes,” Science 314:126-129 (2006). [cited by applicant]
Morgan et al., “Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced with a Chimeric Antigen Receptor Recognizing ERBB2,” Molecular Therapy 18(4):843-851 (2010). [cited by applicant]
Naldini et al., “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector,” Science 272(5259):263-267 (1996). [cited by applicant]
Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,” J. Mol. Biol. 48:443-453 (1970). [cited by applicant]
Ono et al., “Plasmid DNAs directly injected into mouse brain with lipofectin can be incorporated and expressed by brain cells,” Neuroscience Letters, 117:259-263 (1990). [cited by applicant]
Ozhegov, S.I. The Thesaurus of the Russian Language: 80,000 words and idioms / S.I. Ozhegov and N. Yu Shvedova; Russian Academy of Sciences, Institute of the Russian Language named after V.V. Vinogradov.—4th Edition, up… [cited by applicant]
Panelli et al., “A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12,” J Immunol 164:4382-4392 (2000). [cited by applicant]
Panelli et al., “Expansion of Tumor-T Cell Pairs from Fine Needle Aspirates of Melanoma Metastases,” J Immunol 164:495-504 (2000). [cited by applicant]
Papanicolaou et al., “Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele,” Blood 102:2498-2505 (2003). [cited by applicant]
Parkman, R., “Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones,” J. Immunol. 136:3543-3548 (1986). [cited by applicant]
Pastan et al., “Immunotoxins in cancer therapy,” Curr. Opin. Investig. Drugs 3(7):1089-1091 (2002). [cited by applicant]
Paulus, “Preparation and Biomedical Applications of Bi specific Antibodies,” Behring Ins. Mitt. 78: 118-132 (1985). [cited by applicant]
Payne, “Progress in immunoconjugate cancer therapeutics,” Cancer Cell 3:207-212 (2003). [cited by applicant]
Pegram et al., “Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning,” Blood 119(18):4133-4141 (2012). [cited by applicant]
Persic et al., “An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries,” Gene 187:9-18 (1997). [cited by applicant]
Peter et al., “Protective effects of an anti-melanocortin-4 receptor scFv derivative in lipopolysaccharide-induced cachexia in rats,” J Cachexia Sarcopenia Muscle 4:79-88 (2013). [cited by applicant]
Peter et al., “scFv Single Chain Antibody Variable Fragment as Inverse Agonist of the 132-Adrenergic Receptor,” J Biol. Chem. 278(38):36740-36747 (2003). [cited by applicant]
Posthumus et al., “Analysis and Simulation of a Neutralizing Epitope of Transmissible Gastroenteritis Virus,” J. Virology, 64(7):3304-3309 (1990). [cited by applicant]
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc Natl Acad Sci USA 86:10029-10033 (1989). [cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy,” Nature 332:323-327 (1988). [cited by applicant]
Ritter et al., “Serological Analysis of Human Anti-Human Antibody Responses in Colon Cancer Patients Treated with Repeated Doses of Humanized Monoclonal Antibody A33,” Cancer Res 61:6851-6859 (2001). [cited by applicant]
Riviere et al., “Novel Strategies for Cancer Therapy: The Potential of Genetically Modified T Lymphocytes,” Curr Hematol Rep 3:290-297 (2004). [cited by applicant]
Roberts et al., “Vaccination with CD20 peptides induces a biologically active, specific immune response in mice,” Blood 99: 3748-3755 (2002). [cited by applicant]
Rosenberg et al., “Adoptive cell transfer: a clinical path to effective cancer immunotherapy,” Nature Reviews Cancer 8:299-308 (2008). [cited by applicant]
Rosenberg et al., “Gene Transfer into Humans,” N. Engl. J. Med 323(9):570-578 (1990). [cited by applicant]
Rudnick et al., “Affinity and Avidity in Antibody-Based Tumor Targeting,” Can. Biotherp. & Radiopharm 24(2):155-162 (2009). [cited by applicant]
Sadelain et al., “Targeting Tumours With Genetically Enhanced T Lymphocytes,” Nat Rev Cancer 3:35-45 (2003). [cited by applicant]
Sadelain et al., “The basic principles of chimeric antigen receptor (CAR) design,” Cancer Discovery 3(4):388-398 (2013). [cited by applicant]
Sadelain et al., “The promise and potential pitfalls of chimeric antigen receptors,” Curr Opin Immunol 21:215-223 (2009). [cited by applicant]
Saito et al., “Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities,” Adv. Drug Deliv. Rev. 55:199-215 (2003). [cited by applicant]
Saito, G. et al. (2003) Adv. Drug Deliv. Rev. 55:199-215. [cited by applicant]
Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, New York (1989). [cited by applicant]
Search Report in Russian Application No. 2017123545 received by Applicant on Dec. 11, 2019. [cited by applicant]
Senter et al., “Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates,” Adv. Drug Deliv. Rev. 53:247-264 (2001). [cited by applicant]
Sharp, “Gene Therapy,” The Lancet 337: 1277-1278 (1991). [cited by applicant]
Shaughnessy, Jr., et al., “A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1,” Blood 109:2276-2284 (2007). [cited by applicant]
Shen et al., “Engineering Peptide Linkers for scFv Immunosensors,” Anal Chem. 80(6):1910-1917 (2008). [cited by applicant]
Shieh et al., “Transgenic Expression of Single-Chain Anti-CTLA-4 Fv on β Cells Protects Nonobese Diabetic Mice from Autoimmune Diabetes,” J Immunol 183:2277-2285 (2009). [cited by applicant]
Siegel et al., “Cancer Statistics, 2013,” CA Cancer J Clin 63:11-30 (2013). [cited by applicant]
Smith et al. (Sci Transl. Med. 11:1-14 (2019). [cited by applicant]
Stephan et al., “T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection,” Nat. Med 13(12):1440-1449 (2007). [cited by applicant]
Straubinger et al., “Liposomes as Carriers for Intracellular Delivery of Nucleic Acids,” Methods in Enzymology, 101:512-527 (1983). [cited by applicant]
Supplemental Partial European Search Report dated May 4, 2018 in Application No. EP 15865989. [cited by applicant]
Talmadge et al., “Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer,” Am. J. Pathol. 170(3):793-804 (2007). [cited by applicant]
Tang et al., “The Foxp+ regulatory T cell: a jack of all trades, master of regulation,” Nat Inmmunol 9(3):239-244 (2008). [cited by applicant]
The Polymerase Chain Reaction. Mullis, 1994 (Foreword and Table of Contents). [cited by applicant]
Thorpe et al., “The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates,” Immunol. Rev., 62:119-158 (1982). [cited by applicant]
Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review”, in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985). [cited by applicant]
Thurber et al., “Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance,” Adv. Drug Deliv. Rev. 60:1421-1434 (2008). [cited by applicant]
Timmerman et al., “Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS™ technology,” J. Mol. Recognit. 20:283-299 (2007). [cited by applicant]
Tjandra et al., “Development of human anti-murine antibody (HAMA) response in patients,” Immunol Cell Biol. 68:367-376 (1990). [cited by applicant]
Tolstoshev et al., “Gene expression using retroviral vectors,” Current Opinion in Biotechnology 1:55-61 (1990). [cited by applicant]
Tomimatsu et al., “Production of Human Monoclonal Antibodies against FcϵRIα by a Method Combining in Vitro Immunization with Phage Display,” Biosci Biotechnol Biochem 73(7):1465-1469 (2009). [cited by applicant]
Trail et al., “Monoclonal antibody drug immunoconjugates for targeted treatment of cancer,” Cancer Immunol. Immunother. 52:328-337 (2003). [cited by applicant]
Voskoglou-Nomikos et al., “Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models,” Clin Can. Res. 9:4227-4239 (2003). [cited by applicant]
Wahl et al., “Improved Radioimaging and Tumor Localization with Monoclonal F(ab′)2,” J. Nucl. Med. 24:316-325 (1983). [cited by applicant]
Wang et al., “Single-Chain Antibody (scFv),” Antibody Technology, Military Medical Science Press, Beijing, pp. 75 (2009) (with full English translation). [cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Wels et al., “Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors,” Cancer Immunol Immunother 53:217-226 (2004). [cited by applicant]
Wolff et al., “Direct Gene Transfer into Mouse Muscle in Vivo,” Science 247(4949):1465-1468 (1990). [cited by applicant]
Written Opinion of Singapore Application No. 11201704547R, dated Jun. 25, 2018. [cited by applicant]
Wu et al., “Receptor-mediated Gene Delivery and Expression in Vivo,” Journal of Biological Chemistry, 263(29):14621-14624 (1988). [cited by applicant]
Wu et al., “Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo,” Journal of Biological Chemistry 264(29):16985-16987 (1989). [cited by applicant]
Xie et al., “Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv,” Nat Biotech 15:768-771 (1997). [cited by applicant]
Xu et al., “Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol,” Exp. Hemat. 22:223-230 (1994). [cited by applicant]
Yasmina Na, et al. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Science 2008; 17(8): 1326-1335. [cited by applicant]
Zhao et al., “Characteristics of an scFv Antibody Fragment That Binds to Immunoglobulin G of Graves' Disease Patients and Inhibits Autoantibody-Mediated Thyroid-Stimulating Activity,” Hybridoma 27(6):445-451 (2008). [cited by applicant]
Zhong et al., “Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment P13kinase/AKT/Bc1-XL Activation and CD8+ T Cell-mediated Tumor Eradication,” Molecular Therapy, pp. 413-420 (2010). [cited by applicant]
Rabia et al., “Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility,” Biochem Eng J (Sep. 15, 2018, e-pub. Jun. 5, 2018) 137:365-374. [cited by applicant]